Roivant Sciences Ltd. Logo

Roivant Sciences Ltd. (ROIV)

NASDAQ

Currency in USD
40.94
-0.87 (-2.08%)

Closed

Sep 10, 2026

Day's Range

40.22
41.41

52 wk Range

13.39
42.50

Profile - ROIV - Roivant Sciences Ltd.

Profile

Mic Code

XNGS

Sector

Healthcare

Industry

Biotechnology

Employees

750


Roivant Sciences Ltd. is an American multinational healthcare company that develops transformative medicines and technologies by creating agile, focused subsidiaries called Vants. These Vants target specific therapeutic areas, including autoimmune diseases through Immunovant, severe autoimmune conditions via Priovant, and pulmonary diseases with Pulmovant. The company applies technology across drug discovery, development, and commercialization to accelerate the delivery of innovative therapies to patients. Roivant Sciences Ltd. maintains a broad pipeline of investigational drugs across multiple areas such as immunology, dermatology, rare diseases, and inflammatory conditions. Notable Vants include Kinevant for rare autoimmune and inflammatory diseases, and health technology units like Datavant for healthcare data sharing and Lokavant for clinical trial optimization. Founded in 2014 and headquartered in New York City with offices in Boston and Basel, Roivant Sciences Ltd. operates as a parent to these specialized entities, aligning incentives for efficient execution in the biopharmaceutical sector.

Profile Details

Type

Common Stock

Ceo

Mr. Matthew Gline

Address

11-12 St. James's Square

City

London

Zip

SW1Y 4LB

Country

United Kingdom

Phone

44 20 7400 3347

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Charting by TradingView.

Last updated:

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.